

18. TROUBLE SHOOTING CHART

PROBLEM	POSSIBLE CAUSE	SOLUTION
1. Controls out of validation limit	a) Controls/ calibrator deterioration due to improper storage or used	Use controls/ calibrator within 30 days once opened and Check storage after expiry. temp. It should be 2-8°C.
	b) Cross contamination	Pipette carefully and do not of Controls interchange caps.
	c) Reagents deterioration due to improper storage or used after expiry.	Use reagents within 30 days once opened and Check storage temp. It should be 2-8°C.
	d) Magnetic microsphere are not properly mixed before loading in the analyzer.	Ensure proper mixing of bottle containing microspheres by gentle shaking/ inversion before use.
2) High Insulin test results	a) Use of turbid, lipaemic or hemolyzed sample.	Use clear fresh sample. Refer specimen collection, handling and processing for more details.
	b) Sample position is wrongly defined while loading the sample details in analyzer.	check the sample position and run the test meticulously.
	c) Magnetic microsphere are not properly mixed before loading in the analyzer.	Ensure proper mixing of bottle containing microspheres by gentle shaking/ inversion before use.
	d) Wrong Sample identification	Make sample I.D. at the time of sample Collection.
3) Low Insulin test results	a)Sample deterioration due to improper Storage or microbially contaminated sample.	Use clear fresh sample immediately after collection. Refer Specimen collection, and handling processing for more details.
	b) Sample position is wrongly defined while loading the sample details in analyzer.	check the sample position and run the test meticulously.
	c) Magnetic microsphere are not properly mixed before loading in the analyzer.	Ensure proper mixing of bottle containing microspheres by gentle shaking/ inversion before use.
	d) Wrong Sample identification	Make sample I.D. at the time of sample Collection.

in vitro diagnostic Reagent, not for medicinal use

J. Mitra & Co. Pvt. Ltd.
A 180-181, Okhla Ind. Area, Ph-1, New Delhi-110 020, INDIA
Ph: +91-11-47130300, 47130500
e-mail: jmitra@jmitra.co.in Internet: www.jmitra.co.in

VER-01 P-00

MNV/...
Rev. Date: Aug-24

INSULIN iClia

Chemiluminescence microparticle immunoassay for Quantitative Measurement of insulin (INS) in Human Serum/Plasma

1. INTRODUCTION

Insulin (INS) is secreted by islet beta cells in the islet. Insulin is the only hormone in the body to reduce blood sugar, but also the only hormone to promote glycogen, fat, protein synthesis. Insulin promotes glucose uptake and utilization by tissues and cells throughout the body, and inhibits glycogen decomposition and gluconeogenesis. When glucose levels return to baseline, insulin levels also return to baseline. Insufficient secretion of insulin is the main cause of high blood sugar and diabetes. It is mainly used for the pathophysiology of diabetes mellitus and the function evaluation of islet β cells, the differential diagnosis of insulin-dependent diabetes mellitus and non-insulin-dependent diabetes mellitus, and the etiological evaluation of fasting hypoglycemia and certain insulinemia. One of the main clinical applications of insulin is in the diagnosis and management of diabetes, which is caused by insufficient glucose uptake in tissues, resulting in chronic hyperglycemia. Diabetes has serious complications such as kidney failure, heart disease, nerve damage, blindness and gangrene. Severe episodes of hyperglycemia can lead to ketoacidosis and coma.

2. INTENDED USE

Insulin iClia Kit is intended for the *in vitro* quantitative measurement of insulin (INS) in human serum/plasma as an aid in evaluating the function of pancreatic islets. The assay kit is intended for in-vitro diagnostic use. This kit is only operational in conjunction with J.Mitra CLIA 181 Analyzer.

3. PRINCIPLE

Insulin iClia Diagnostic Kit is a sandwich immunoassay for determination of Insulin in human serum and plasma using chemiluminescent technology.

In the first step, anti-Insulin labeled magnetic microparticle, human serum, assay buffer and an anti- Insulin labeled acridinium ester (AE Conjugate) are mixed and incubated in an assay tube, which allows patient specific Insulin to bind to microparticle. After sample matrix is removed by washing, the Microparticle-anti- Insulin antibody/antigen/antibody immune complex is kept with the help of a magnetic separator. Excess acridinium ester conjugate is removed by washing and finally the bound enzyme is detected by addition of chemiluminescent substrate.

The relative light unit (RLU) intensity is proportional to the amount of Insulin. According to the Insulin RLU-concentration standard curve, the RLU tested can be interpreted to Insulin concentration in the sample expressed as ng/mL.

4. DESCRIPTION OF SYMBOLS USED

The following are graphical symbols used in or found on J. Mitra diagnostic products and packing. These symbols are the most common ones appearing on medical devices and their packing. They are explained in more detail in the European Standard EN ISO 15223-1:2021.

	Manufactured By		<i>In vitro</i> diagnostic medical device
	No. of tests Lot Number		Instruction for use
	Batch Number		Temperature Limitation
	Manufacturing Date		Caution - See instruction for use
	Expiry Date		Catalogue Number
	Do not use if package is damaged		Keep away from sunlight
	Contains biological Material of Human Origin		Contains biological Material of Animal Origin
	Country of Manufacture		Keep Dry

5. KIT PRESENTATION

- 25 Test Pack
- 50 Test Pack
- 100 Test Pack

6. KIT & ITS COMPONENTS

COMPONENT	DESCRIPTION
Microparticle Buffer	Magnetic Microspheres coated with anti-Insulin antibodies with preservatives.
Assay Buffer	Tris buffer and BSA with preservative.
AE Conjugate	anti-Insulin antibodies linked to acridinium ester with Protein stabilizers.
Control-1	Purified Insulin antigen in Tris buffer (pH7.4) with stabilizer.
Control-2	Purified Insulin antigen in Tris buffer (pH7.4) with stabilizer.
Calibrator-1	Low concentration of Insulin antigen in human serum containing preservatives.
Calibrator-2	High concentration of Insulin antigen in human serum containing preservatives.
Reagent Plugs	Silicon caps to cover the opened reagents.

7. STORAGE AND STABILITY

The shelf-life of the kit is 12 months from the date of manufacturing, when stored at 2-8°C. **Once the kit is opened, onboard stability of reagents, calibrator and control is 30 days at 2-8°C.**

8. ADDITIONAL MATERIAL AND INSTRUMENTS REQUIRED

- **Pre-Trigger Solution:** Hydrogen peroxide solution.
- **Trigger Solution:** Sodium hydroxide solution.
- **Wash Buffer:** Phosphate buffered saline solution with surfactant.
- **Assay Cup**
- **Sample Diluent**
- **J. Mitra CLIA Analyzer**

All materials and analyzer to be used for running the Insulin iClia shall be from J. Mitra & Co. Pvt. Ltd.

9. SPECIMEN COLLECTION & HANDLING

1. Only human serum or plasma samples should be used for the test.
2. For serum collection use serum vacutainer. While preparing serum samples, remove the serum from the clot as soon as possible to avoid hemolysis. Fresh serum/plasma samples are preferred.
3. For plasma collection: use Dipotassium EDTA, Tripotassium EDTA, Sodium heparin and lithium heparin gel vacutainer.
4. Specimens should be free of microbial contamination and may be stored at 2-8°C for one week, or frozen at -20°C or lower. Avoid repeated freezing and thawing.
5. Do not use heat inactivated samples as their use may give false results. Hemolyzed and Icteric hyperlipemic samples may give erroneous results.
6. Serum specimens from patients receiving anticoagulant or thrombolytic therapy may contain fibrin due to incomplete clot formation.
7. Always use clear specimens. Centrifuge viscous/ thick or turbid specimen at 10,000 RPM for 15 minutes prior to use to avoid inconsistent result.
8. Use of disposable pipettes or pipette tips is recommended to prevent cross contamination.

10. SPECIMEN PROCESSING

(A) FROZEN SAMPLE

Insulin iClia test is best used with fresh samples that have not been frozen and thawed. However most frozen samples will perform well if the procedure suggested below is followed.

Allow the frozen sample to thaw in a vertical position in the rack. Do not shake the sample. This allows particles to settle to the bottom. Centrifuge the sample at 10,000 rpm for 15 minutes.

(B) TRANSPORTATION

If the specimen is to be transported, it should be packed in compliance with the current Government regulations regarding transport of aetiologic agents.

11. WARNING & PRECAUTION

 **CAUTION:** THIS KIT CONTAINS MATERIALS OF HUMAN ORIGIN. NO TEST METHOD CAN OFFER COMPLETE ASSURANCE THAT HUMAN BLOOD PRODUCTS WILL NOT TRANSMIT INFECTION. NEGATIVE CONTROL, POSITIVE CONTROL & ALL THE SAMPLES TO BE TESTED SHOULD BE HANDLED AS THOUGH CAPABLE OF TRANSMITTING INFECTION.

1. The use of disposable gloves and proper biohazardous clothing is STRONGLY RECOMMENDED while running the test.
2. In case there is a cut or wound in hand, DO NOT PERFORM THE TEST.
3. Do not smoke, drink or eat in areas where specimens or kit reagents are being handled.
4. Tests are for *in vitro* diagnostic use only and should be run by competent person only.
5. Do not pipette by mouth.
6. All materials used in the assay and samples should be decontaminated in 5% sodium hypochlorite solution for 30-60 min. before disposal or by autoclaving at 121°C at 15psi for 60 minutes. Do not autoclave materials or solution containing sodium hypochlorite. They should be disposed off in accordance with established safety procedures.
7. Wash hands thoroughly with soap or any suitable detergent, after the use of the kit. Consult a physician immediately in case of accident or contact with eyes, in the event that contaminated material are ingested or come in contact with skin puncture or wounds.
8. Spills should be decontaminated promptly with Sodium Hypochlorite or any other suitable disinfectant.

12. PRECAUTIONS FOR USE & REAGENT HANDLING

1. Do not use kit components beyond the expiration date which is printed on the kit.
2. Store the reagents & samples at 2-8°C.
3. Do not pool reagents from within a batch or between different batches, as they are optimised for individual batch to give best results.
4. Before loading the reagent kit in the clia analyzer for the first time, ensure proper mixing of microparticle bottle to resuspend microparticles that may have settled during transport or storage.
5. Once reagents are opened, reagent plug must be used to prevent reagent evaporation and contamination and to ensure reagent integrity. Reliability of assay results cannot be guaranteed if reagent plugss are not used according to the instructions given.
6. Mark the test specimen with patient's name or identification number. Improper identification may lead to wrong result reporting.
7. To avoid contamination, wear clean gloves when placing a reagent plug on an uncapped reagent bottle.
8. Once a reagent plug has been placed on an open reagent bottle,do not invert the bottle as this will result in reagent leakage and may compromise assay results.
9. Reagents may be stored on or off the Chemiluminescence immunoassay analyzer. If reagents are removed from the analyzer, store them at 2-8°C

(with Reagent plugs) in an upright position. For reagents stored off the system, it is recommended that they should be stored in their original trays and boxes to ensure they remain upright. If the microparticle bottle does not remain upright (with a Reagent plugs placed) while in refrigerated storage off the system, the reagent kit must be discarded.

10. Run Insulin Control-1 & Insulin Control-2 in each assay to evaluate validity of the kit.
11. Distilled or deionised water must be used for wash buffer preparation.
12. Avoid strong light exposure during the assay.
13. In case of any doubt the run should be repeated.

13. TEST PROCEDURE

Assay Procedure

1. Refer to the Clia-181 user manual for detailed information on preparing the analyzer.
2. Before loading the Insulin iClia reagent tray on the analyzer for the first time, mix contents of the microparticle buffer bottle to resuspend microparticles that may have settled during transporation/ storage. Once the microparticles have been loaded, no further mixing is required.

Important Note: Swirl the microparticle (RA) bottle 30 times. Visually inspect the bottle to ensure microspheres are resuspended. If microspheres are still adhered to the bottle, continue to Swirl the bottle until the microspheres have been completely resuspended. If the microspheres do not resuspend, DO NOT USE. Once the microspheres have been resuspended, remove the cap and place the the reagent plug on the bottle to make it ready to use. Remove the cap of (RA), (RB), (RC) and (RD) bottles and place the reagent plugs before use as follow:

(RA) & (RB) : Natural color plug
(RC) : Purple color plug
(RD) : Brown color plug

3. Load the Insulin iClia reagent tray on the Chemiluminescence immunoassay analyzer.
4. Verify that all necessary reagents are available in the reagent tray.
5. Ensure that adequate sample volume (not less than 250 μ L) is present in sample tube prior to running the test.
6. Sample volume required for each additional test from same sample tube is 30 μ L.
7. The Insulin test-specific parameters are stored in reagent barcode placed on the reagent tray and read through barcode reader. In cases, the barcode cannot be read, contact customer support at: 011-47130300, 500 or write us at: jmitra@jmitra.co.in.
8. Run calibration, if required.
9. Mix Insulin iClia calibrators and controls by gentle inversion before use. Open the the cap and place the Insulin Calibrator-1 & Insulin Calibrator-2 and Insulin Control-1 & Insulin Control-2 vials into each respective sample positions. Read the barcode for calibrator and controls provided with the kit.
10. Press START. The test result for first sample will be obtained at 30 minutes.
11. The Chemiluminescence immunoassay analyzer performs all the functions automatically and calculate the results.

Calibration

1. Traceability: This assay has been standardized against the Roche Insulin reagent kit.
2. Every Insulin iClia kit has a two-dimension code label containing the predefined master curve of the particular reagent lot.
3. Test all 2 Calibrators in triplicate. Both Insulin Control-1 and Insulin Control-2 must be tested in each run to evaluate the assay calibration. Ensure that controls values are within the validity range specified in the Insulin iClia QC data sheet given in the Clia Analyzer.

4. Once calibration is accepted (within range) and stored, all subsequent samples may be tested without further calibration unless:
5. Recalibrate the analyzer in following conditions:
 - a) After each exchange/use of new lot (Test reagent and pritrigger/ Trigger solution/wash buffer).
 - b) Every 15 days at the time of any component to be changed.
 - c) Controls are out of validation range.
 - d) Required by pertinent regulations.
 - e) After specified service procedures have been performed or maintenance to critical part or subsystems that might influence the performance of the Insulin iClia.

Result Calculation

The analyzer automatically calculates the concentration of each sample. The results are given in ng/ml.

Result Interpretation

If sample concentration is lower than the lower limit of the linear range, report the result <2.00 iIU/mL, while > 500.00 iIU/mL when it is higher than the upper limit of linear range.

Determination of Reference Interval

Reference Intervalof this assay is considered as 2.00 to 24.00 iIU/mL for healthy people, which is established referring to literatures, based on the rest results of more than 60 clinical samples.Due to the differences in geography, race, gender or age, it is suggested each laboratory establish its own reference interval or conduct verification of the existing reference interval.

14. PERFORMANCE CHARACTERISTICS

- Assay results obtained in individual laboratories may vary from data presented in this product insert.

Limit of Blank (LoB)

- The Limit of Blank was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A requirements.
- The Limit of Blank is the 95th percentile value from n >20 measurements of analyte free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95%.
- The observed LoB value was $\leq 1.00 \mu$ IU/ml.

Accuracy: The accuracy of Insulin iClia was detected with 60 clinical specimens and compared with Roche CLIA. The co-relation co-efficient is >0.95.

Precision

Intra Assay Variation

Within run variation was determined by 10 replicate measurements of two different Insulin control sera(Low) and (High) in one assay in 3 different lots. The within assay variability is <10%.

Inter Assay Variation

Between run variation was determined by 10 replicate measurements in 10 sequential days of two different control sera(Low) and (High)in 3 different lots.The between assay variability is <10%.

Intra-Assay, n=10			Inter-Assay, n=10×2		
Control	Mean (ng/ml)	CV	Sample	Mean (ng/ml)	CV
1	0.49	4.37%	1	0.52	6.19%
2	22.70	3.80%	2	22.84	7.56%

Inter machine(CLIA-181 Analyzer) Variation

Between machine variation was determined by 3 replicate measurements of two different Insulin control sera(Low) and (High)in 3 different lots in 3 different CLIA-181 Analyzer. The between machine variability is <10.0 %.

Linearity

The linearity was determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP6-A requirements.

The linearity range was verified by more than 6 concentration levels which encompass or be equal to the minimum and the maximum values of linearity range and duplicate assays in triplicate in single run for each lot at all 6 levels.

The Insulin iClia kit has been demonstrated to be linear from is 0.025 ng/ml to 50.000 ng/ml, regression (R²) of more than ≥ 0.990 .

Interference

A study was performed based on guidance from CLSI EP7-A2.

Potentially interfering substances were evaluated to determine whether Insulin concentrations were affected when using the Insulin iClia kit. Samples containing the potential interferents were prepared at two Insulin concentrations. The samples were assayed, and the Insulin concentrations of the spiked samples were compared to the reference samples.

Potential Interferent	Interferent Concentration	% Interferent Bias
Bilirubin	20 mg/dL	<10%
Hb	500 mg/dL	<10%
Triglyceride	1000 mg/dL	<10%
Total protein	10 g/dL	<10%
RF	1000IU/mL	< 10%
ANA	400AU/mL	< 10%
HAMA	600ng/mL	< 10%

15. LIMITATION OF THE TEST

- The Insulin iCia should be used for detection of Insulin in serum or plasma only and not in other body fluids.
- Results should be used in conjunction with other data; e.g., symptoms, results of other tests, and clinical impressions, If the Insulin results are inconsistent with clinical evidence, additional testing is recommended.
- Clinical diagnosis should not be made on the findings of a single test result, but should be integrated with all clinical and laboratory findings.
- Samples of lipid, hemolysis or jaundice may result in incorrect results. Hemoglobin (150 mg/dL), triglyceride (1000 mg/dL), or bilirubin (40 mg/dL) will have no significant interference for the results.

16. LIMITED EXPRESSED WARRANTY DISCLAIMER

The manufacturer limits the warranty to the test kit, as much as that the test kit will function as an *in vitro* diagnostic assay within the limitations and specifications as described in the product instruction-manual, when used strictly in accordance with the instructions contained therein. The manufacturer disclaims any warranty expressed or implied including such expressed or implied warranty with respect to merchantability, fitness for use or implied utility for any purpose. The manufacture's liability is limited to either replacement of the product or refund of the purchase price of the product and in no case liable to for claim of any kind for an amount greater than the purchase price of the goods in respect of which damages are likely to be claimed.

The manufacturer shall not be liable to the purchaser or third parties for any injury, damage or economic loss, howsoever caused by the product in the use or in the application there of.

17. REFERENCES

1. Role of Insulin in Health and Disease: An Update., Md Saidur Rahman, Khandkar Shaharina Hossain, Sharnali Das, Sushmita Kundu, Elikanah Olusayo Adegoke,¹ Md. Ataur Rahman, Md. Abdul Hannan, Md Jamal Uddin, and Myung-Geol Pang
2. Insulin Resistance: From Mechanisms to Therapeutic Strategies Shin-Hae Lee, Shi-Young Park, and Cheol Soo Choi.
3. Insulin: A review of analytical methods. Yixiao Shen, Witoon Prinyawiwatkul, Zhimin
4. Wearable Insulin Biosensors for Diabetes Management: Advances and Challenges Sotiria D. Psoma^a and Chryso Kanthou